The patent broadens CTT's IP moat in oral drug delivery, but the stock trades on OTC with no revenue disclosed. Monitor for any partnership, licensing deal, or product launch announcement that would monetize this patent. Without financial data, the near-term price impact is speculative.
Price Chart
Executive Summary
CTT Pharmaceutical Holdings received a continuation-in-part (CIP) patent approval from the USPTO for its micelle delivery technology, covering nicotine, vitamins, and caffeine for use in dissolvable strips, gum, pouches, lozenges, and dissolving tablets. The patent became effective August 11, 2026. This is a positive intellectual property development that broadens the company's addressable product categories, but the filing contains no financial data, revenue, or commercialization timeline, making the near-term trading impact uncertain for this pre-revenue OTC stock.
Key Facts
- CTT received a continuation-in-part (CIP) patent approval from the USPTO for its micelle delivery technology.
- The patent covers nicotine, vitamins, and caffeine formulations.
- The patent allows the technology to be used in dissolvable strips, gum, pouches, lozenges, and dissolving tablets.
- The patent was issued a patent number and became effective August 11, 2026.
- The filing contains no financial data, revenue figures, or commercialization agreements.
Financial Impact
No financial figures provided in the filing; the patent is an IP asset with no disclosed revenue or deal value.
Risk Factors
- No revenue or commercialization timeline disclosed; the company is pre-revenue.
- OTC listing carries higher volatility and lower liquidity.
- Patent alone does not guarantee commercial success or partnership interest.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171520-26-000225 |
| Exhibit: ex99-1.htm | 0001171520-26-000225 |
| Document: 0001171520-26-000225-index-headers.html | 0001171520-26-000225 |
| Document: 0001171520-26-000225-index.html | 0001171520-26-000225 |
| Document: 0001171520-26-000225.txt | 0001171520-26-000225 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $0.0566 | awaiting T+60 | — | $0.0570 (+0.71%) |
Oct 7, 2026 20d ago | 8-K | $0.0566 | awaiting T+60 | — | $0.0570 (−0.71%) |
Aug 12, 2026 10w ago | 8-K | $0.0660 | awaiting T+60 | — | $0.0570 (−13.64%) |
Jul 24, 2026 13w ago | S-1/A | $0.0660 $0.0589 | ▲ +10.76% | ▲ +14.31% | $0.0570 (+13.64%) |
Jun 29, 2026 17w ago | S-1/A | $0.0750 $0.0485 | ▲ +35.33% | ▲ +38.38% | $0.0570 (+24.00%) |
Jun 16, 2026 19w ago | S-1/A | $0.0800 $0.0518 | ▲ +35.25% | ▲ +38.66% | $0.0570 (+28.75%) |
May 29, 2026 21w ago | S-1/A | $0.0720 $0.0570 | ▲ +20.83% | ▲ +22.02% | $0.0570 (+20.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers